Rare diseases
Investigational molecules
Locations
Recruiting trials first
1 clinical trial in this condition
GermanyIn short
Skin angiosarcoma is a rare and aggressive cancer that develops from the cells lining blood vessels, most commonly appearing on the head and neck of older adults. Because it can look like a bruise that won't fade, early detection and proper testing are essential for starting treatment as soon as possible.
Skin angiosarcoma is an uncommon cancer that affects the inner lining of blood vessels in the skin. While anyone can develop this condition, it mostly appears in people over 60 years old, particularly affecting the scalp, face, and neck areas. Understanding when to seek medical attention is crucial because early diagnosis can significantly impact treatment outcomes.
You should consider seeking diagnostic evaluation if you notice any unusual changes in your skin that don't improve over time. A lesion, which is simply an area of abnormal tissue, that resembles a bruise but doesn't fade away is one of the most common early signs. Unlike ordinary bruises that gradually disappear, these areas tend to grow larger and may develop into raised patches or nodules.
Anyone experiencing a rapidly growing lump under the skin, particularly on the head or neck, should consult a healthcare provider promptly. The condition deserves immediate attention if the affected area bleeds easily when touched, scratched, or bumped. Similarly, if you notice swelling around a bruise-like mark that persists for weeks, this warrants professional evaluation.
People who have previously undergone radiation therapy face higher risk and should be especially vigilant about skin changes. Angiosarcoma can develop many years after radiation treatment, typically eight to ten years later. Those with chronic swelling in their arms or legs, a condition called lymphedema, also need to watch for unusual skin changes, as this increases their risk of developing angiosarcoma.
The diagnostic journey typically begins with a thorough physical examination by your healthcare provider. During this examination, the doctor carefully inspects the suspicious area of skin, noting its appearance, size, color, and texture. They will look for characteristic features such as purple or reddish discoloration, raised areas, or lesions that resemble bruises but don't fade over time.
Your doctor will also feel the affected area to assess whether there is swelling, tenderness, or any lumps beneath the skin surface. They'll examine nearby lymph nodes to check for enlargement, which could indicate that the cancer has spread. During this examination, your healthcare provider will ask detailed questions about when you first noticed the changes, whether the area has grown, if it bleeds easily, and whether you've experienced any pain or discomfort.
The physical exam also involves taking a complete medical history. Your doctor needs to know about any previous cancer treatments, especially radiation therapy, as this is a known risk factor for developing angiosarcoma. They'll also ask about chronic swelling in your limbs, exposure to certain chemicals, and whether any family members have had similar conditions.
A biopsy is the most important diagnostic procedure for confirming skin angiosarcoma. This test involves removing a small sample of the suspicious tissue so that specialists can examine it under a microscope. Without a biopsy, doctors cannot definitively determine whether a skin lesion is angiosarcoma or another condition.
During the biopsy procedure, your doctor removes a portion of the abnormal tissue using a needle or a small surgical instrument. The sample is then sent to a laboratory where a specialist called a pathologist examines the cells under a microscope. The pathologist looks for specific characteristics that distinguish angiosarcoma cells from normal cells and from other types of cancer.
Special tests are often performed on the biopsy sample to provide more detailed information about the cancer cells. These tests can help identify specific proteins or markers that confirm the diagnosis of angiosarcoma. The results from these specialized examinations give your healthcare team crucial information about the nature of the tumor and help guide treatment decisions.
Once skin angiosarcoma is suspected or confirmed, imaging tests help determine the extent of the disease. These tests create detailed pictures of the inside of your body, allowing doctors to see whether the cancer has spread beyond the original site. The choice of imaging tests depends on your specific situation and the location of the tumor.
Magnetic Resonance Imaging (MRI) uses powerful magnets and radio waves to create detailed images of soft tissues. For skin angiosarcoma, MRI scans can show the size of the tumor, how deeply it extends into surrounding tissues, and whether it has affected nearby structures. This information is essential for planning surgery or other treatments.
Computed Tomography (CT) scans use X-rays taken from different angles to create cross-sectional images of your body. These scans are particularly useful for checking whether angiosarcoma has spread to internal organs such as the lungs or liver. CT scans are often performed on the chest and abdomen to look for signs of disease spread.
Positron Emission Tomography (PET) scans involve injecting a small amount of radioactive sugar into your bloodstream. Cancer cells, which use more energy than normal cells, absorb more of this sugar and show up as bright spots on the scan. PET scans can help identify areas of active cancer throughout the body, which is valuable information when determining the stage of the disease.
Ultrasound examinations may also be used, particularly for evaluating skin and superficial tissue involvement. This test uses sound waves to create pictures of the inside of your body. It's painless and doesn't involve radiation, making it a safe option for initial evaluation or for monitoring changes over time.
One of the challenges in diagnosing skin angiosarcoma is that it can look very similar to other, less serious conditions. In its early stages, angiosarcoma often appears as a purple or reddish area that resembles a simple bruise or a rash. This similarity can lead to delays in diagnosis, which is why understanding the distinguishing features is so important.
Unlike ordinary bruises that gradually fade and disappear within weeks, angiosarcoma lesions persist and grow larger over time. They may also spread to surrounding areas of skin, creating multiple patches rather than staying in one place. The affected area might develop a raised, nodular appearance or begin to bleed spontaneously or with minimal trauma.
During the diagnostic process, doctors must rule out other skin conditions that can appear similar. These include vascular malformations, benign blood vessel tumors called hemangiomas, inflammatory skin conditions, and even bacterial skin infections. The biopsy with specialized testing is what ultimately distinguishes angiosarcoma from these other possibilities.
Clinical trials are research studies that test new treatments or approaches for managing angiosarcoma. Participating in a clinical trial can provide access to innovative therapies that aren't yet widely available. However, before you can enroll in a clinical trial, you must undergo specific diagnostic tests to determine whether you meet the study's eligibility criteria.
Clinical trials for angiosarcoma typically require confirmation of the diagnosis through a biopsy. The tissue sample must show clear evidence of angiosarcoma when examined by a pathologist. Many trials also require that the biopsy be recent, often performed within a specific timeframe before enrollment, to ensure that the diagnosis is current.
Imaging studies are essential components of clinical trial screening. Trials often require baseline imaging to document the size and location of all visible tumors before treatment begins. These images serve as comparison points to measure how well the treatment is working during the trial. Common imaging requirements include CT scans of the chest, abdomen, and pelvis, as well as MRI scans of the primary tumor site.
Blood tests are frequently required to assess your overall health and organ function. These tests check your blood cell counts, liver function, kidney function, and other important markers. The results help determine whether you're healthy enough to tolerate the experimental treatment being studied in the trial. Some trials have specific requirements for these values, such as minimum blood cell counts or maximum levels of certain liver enzymes.
Some clinical trials require specialized testing on the tumor tissue to identify specific characteristics of the cancer. For example, trials testing targeted therapies may require analysis of certain proteins or genetic markers in the tumor cells. These tests help identify patients whose angiosarcomas are most likely to respond to the specific treatment being studied.
Researchers are particularly interested in certain features of angiosarcoma tumors, such as PD-L1 positivity, which is a protein marker that can indicate how the tumor interacts with the immune system. Tumors that express this marker might respond better to immunotherapy treatments. Other trials might look for high tumor mutational burden, which means the cancer cells have many genetic changes that could make them vulnerable to certain types of treatment.
Performance status evaluation is another standard requirement for clinical trial participation. This assessment measures how well you can perform daily activities and how the cancer affects your overall functioning. Doctors use standardized scales to rate your performance status, and most trials require that participants have a certain level of functioning to ensure they can safely tolerate the treatment.
Documentation of disease stage and extent is crucial for trial enrollment. Researchers need to know whether your angiosarcoma is localized to the original site or has spread to other parts of your body. Many trials specifically recruit patients with either early-stage or advanced-stage disease, so accurate staging through comprehensive imaging and examination is necessary.
The outlook for skin angiosarcoma varies considerably from person to person and depends on multiple factors. Your individual prognosis depends largely on where the tumor is located in your body, whether the cancer has spread to other areas, and how much of the tumor can be removed during surgery.
Several factors influence the likely course of the disease. Tumors located on the scalp and neck tend to have worse outcomes compared to those in other locations. This is partly because these areas have rich blood supplies, which can facilitate cancer spread. Larger tumors, particularly those greater than 5 centimeters in size, are associated with poorer prognosis than smaller ones.
Age plays a significant role in outcomes, with increasing age generally associated with worse prognosis. The presence of multiple skin lesions rather than a single tumor also suggests more aggressive disease and poorer outcomes. Additionally, if the tumor shows signs of tissue death, called necrosis, when examined under the microscope, this typically indicates a more aggressive cancer.
Whether the cancer has spread, or metastasized, to other parts of the body is one of the most important factors affecting prognosis. Angiosarcoma has a high tendency to spread to distant organs, most commonly the lungs and liver. When cancer has already spread at the time of diagnosis, the prognosis is significantly worse than when it remains localized.
The amount of tumor that can be removed during surgery also impacts outcomes. When surgeons can remove all visible cancer with clear margins, meaning they also take out a rim of normal tissue around the tumor, patients generally have better outcomes. However, achieving complete removal with clear margins can be challenging, especially for tumors on the head and neck where preserving function and appearance is important.
Skin angiosarcoma has a poor overall prognosis compared to many other types of cancer. Studies show that three-year survival rates can be as low as 40%, and five-year survival rates as low as 17%. These numbers represent averages across many patients and may not reflect your individual situation.
Survival rates have improved over time, likely due to earlier diagnosis and more effective treatments. Research comparing outcomes from different time periods shows better survival for patients diagnosed more recently compared to those diagnosed several decades ago. This trend suggests that advances in medical care are making a positive difference.
Patients with breast angiosarcoma, particularly low-grade tumors, tend to survive longer than people with other types of angiosarcoma. However, many people with angiosarcoma aren't diagnosed until their cancer has already spread to other parts of the body, which often results in worse outcomes.
It's important to remember that survival statistics are estimates based on large groups of people. They cannot predict exactly what will happen to any individual person. Your healthcare team can provide more personalized information based on your specific circumstances, including the stage of your disease, your overall health, and how your cancer responds to treatment.
This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
